Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progestogens with antiandrogenic properties.

Daniel Raudrant1, Thomas Rabe

  • 1Hôtel Dieu, Lyon, France.

Drugs
|February 26, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ovarian tissue cryopreservation and transplantation - first baby in China.

Climacteric : the journal of the International Menopause Society·2022
Same author

Corrigendum to "Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate".

BioMed research international·2019
Same author

Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate.

BioMed research international·2018
Same author

Symptoms of uterine myomas: data of an epidemiological study in Germany.

Archives of gynecology and obstetrics·2016
Same author

Prevalence of uterine myomas in women in Germany: data of an epidemiological study.

Archives of gynecology and obstetrics·2015
Same author

Hyperandrogenemia in polycystic ovary syndrome: exploration of the role of free testosterone and androstenedione in metabolic phenotype.

PloS one·2014
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Combined oral contraceptives with antiandrogenic progestogens offer effective contraception and improve androgen-related conditions like acne and hirsutism. These options are well-tolerated and beneficial for women with existing androgen disorders.

Area of Science:

  • Endocrinology
  • Dermatology
  • Gynecology

Background:

  • Potent progestogens like chlormadinone acetate, cyproterone acetate, and dienogest exhibit antiandrogenic activity.
  • These progestogens block androgen receptors and inhibit 5alpha-reductase, reducing androgenic effects in skin and hair follicles.
  • Certain progestogens also suppress gonadotropin secretion, decreasing ovarian and adrenal androgen production.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of combined oral contraceptives (COCs) containing antiandrogenic progestogens.
  • To assess their impact on androgen-related dermatological conditions and their contraceptive performance.
  • To determine their suitability for women with androgen-related disorders and those seeking improved skin and hair health.

Main Methods:

Related Experiment Videos

  • Review of clinical data on COCs containing chlormadinone acetate or cyproterone acetate combined with ethinylestradiol.
  • Analysis of contraceptive efficacy using Pearl indices.
  • Assessment of outcomes for seborrhoea, acne, hirsutism, and alopecia in users.

Main Results:

  • COCs demonstrated highly effective contraception with excellent cycle control (Pearl indices: 0-0.7).
  • Significant improvement or resolution of seborrhoea (80%), acne (59-70%), hirsutism (36%), and alopecia (up to 86%) was observed.
  • Adverse effects were generally mild and comparable to standard COCs, with no significant impact on metabolic or liver functions.

Conclusions:

  • COCs with antiandrogenic progestogens provide reliable contraception and effectively manage androgen-related disorders.
  • These contraceptives are well-tolerated and offer additional benefits for women concerned about skin and hair conditions.
  • They represent a valuable therapeutic option for women requiring contraception and managing hyperandrogenism.